Edwards Lifesciences shares are lower today as investors react to renewed analyst skepticism around the company’s growth trajectory in 2025–2026, particularly in TAVR, which remains the core earnings driver. The latest analyst commentary centers on expectations that growth will remain below prior bullish assumptions, prompting reductions to revenue and profit forecasts and weighing on the multiple investors are willing to pay for the stock. (tipranks.com)

The near-term debate is less about whether Edwards can grow and more about how fast—and whether the company can re-accelerate above the roughly low-double-digit threshold investors once priced in. Analysts pointing to sub-10% growth expectations over the next couple of years are pushing the narrative that the risk/reward is less compelling without a clearer catalyst, keeping pressure on the stock when it rallies. (tipranks.com)

Attention is shifting to upcoming clinical and regulatory milestones across the structural heart portfolio, including timelines around EVOQUE clinical readouts and broader platform expansion. Separately, recent regulatory developments around the proposed JenaValve acquisition remain a background overhang as the administrative process plays out. (edwards.com)

With EW near the high-$70s, the market is treating the name as a quality franchise but demanding clearer evidence of sustained acceleration before awarding a premium valuation. Near-term trading is likely to stay sensitive to incremental channel checks on TAVR procedure growth, competitive updates, and any changes to 2026 expectations.